title: [Radioprotective properties of indralin combined with cystamine and mexamine].
abstract: The study of indralin radioprotective properties at its joint application with cystamine and mexamine was carried out in the experiments on inbred mice and rats. The mice and rats were exposed to whole-body y-irradiation at a dose of 9.0 and 9.5 Gy, correspondingly. A combined parenteral administration ofindralin and cystamine at a dose of 25 mg/kg showed ponentiaton of indralin radioprotective properties up to a level of the ED50 effect versus the absence of or a weak radioprotective effect in the case of their separate application. In the experiments on rats, indralin (50 mg/kg) and mexamine (12 mg/kg) injected intraperitoneally almost completely eliminated the animal mortality from the intestinal syndrome of acute radiation sickness amounting in the control radiation group to 60% on the 7th day after exposure to radiation at a dose of 9.5 Gy. However, at the above conditions, radioprotectors at these doses had a low-level radioprotective action at the onset of the bone marrow syndrome of acute radiation sickness. Combined application of indralin and mexamine at the same doses and at the same conditions led to a radiation protection 50% as high as in the case when radioprotectors were applied separately at a double dose.
authors.forename: M V
authors.initials: MV
authors.lastname: Vasin
authors.forename: V V
authors.initials: VV
authors.lastname: Antipov
authors.forename: S N
authors.initials: SN
authors.lastname: Komarova
authors.forename: L A
authors.initials: LA
authors.lastname: Semenova
authors.forename: A A
authors.initials: AA
authors.lastname: Galkin
mesh_terms: D008735:5-Methoxytryptamine / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D003538:Cystamine / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D004359:Drug Therapy, Combination; D005260:Female; D005720:Gamma Rays / Q000009:adverse effects*; D007273:Injections, Intramuscular; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D010636:Phenols / Q000008:administration & dosage / Q000627:therapeutic use*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats
chemical_list: D010636:Phenols; D011837:Radiation-Protective Agents; C086896:indralin; D008735:5-Methoxytryptamine; D003538:Cystamine